Moonlake Immunotherapeutics (MLTX) PT Lowered to $12 at Clear Street

MoonLake Immunotherapeutics (MLTX) call put ratio 3.9 calls to 1 put with a focus on October 80 calls as share price down 90%

MoonLake Immunotherapeutics (NASDAQ: MLTX) 30-day option implied volatility is at 198; compared to its 52-week range of 40 to 243. Call put ratio 3.9 calls to 1 put with a focus on October 80 calls as share price down 90%.

Jefferies Downgrades Moonlake Immunotherapeutics (MLTX) to Hold, 'Growing Uncertainty in SLK Path Fwd and Dimmed Commercial Outlook'

Jefferies analyst Kelly Shi downgraded Moonlake Immunotherapeutics (NASDAQ: MLTX) from Buy to Hold with a price target of $8.00 (from $65.00).

The analyst comments "Post Phase III HS results (note) with VELA-2 missing stat sig and VELA-1 showing 17% pbo-adj efficacy falling short of 20-26%... More

Wedbush Reiterates Outperform Rating on Moonlake Immunotherapeutics (MLTX)

Wedbush analyst Yun Zhong reiterated an Outperform rating and $80.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).

The analyst comments "We see the Ph3 VELA data as a big surprise to many if not all investors, and we expect MLTX shares to be under a significant pressure, since now the... More

BTIG Downgrades Moonlake Immunotherapeutics (MLTX) to Neutral

BTIG analyst Julian Harrison downgraded Moonlake Immunotherapeutics (NASDAQ: MLTX) from Buy to Neutral.

For an analyst ratings summary and ratings history on Moonlake Immunotherapeutics click here. For more ratings news on Moonlake Immunotherapeutics click here.

Shares of Moonlake Immunotherapeutics closed at $61.99 yesterday.

Stifel Downgrades Moonlake Immunotherapeutics (MLTX) to Hold

Stifel analyst Alex Thompson downgraded Moonlake Immunotherapeutics (NASDAQ: MLTX) from Buy to Hold with a price target of $13.00 (from $77.00).

The analyst comments: "Top-line data from the Sonelokimab (SLK) Ph3 VELA program in Hidradenitis Suppurativa (HS) are significantly worse than we or the Street anticipated (20%+).... More

RBC Capital Downgrades Moonlake Immunotherapeutics (MLTX) to Sector Perform

RBC Capital analyst Brian Abrahams downgraded Moonlake Immunotherapeutics (NASDAQ: MLTX) from Outperform to Sector Perform with a price target of $10.00 (from $67.00).

The analyst comments: "Our view: SLK's ph.III data in HS may look like a near-miss from a statistical standpoint, with one study at p... More

MoonLake Immunotherapeutics reports mixed phase 3 hidradenitis results

MoonLake Immunotherapeutics (NASDAQ: MLTX) announced results from its phase 3 VELA program testing sonelokimab in patients with moderate to severe hidradenitis suppurativa at 16 weeks.

The VELA-1 trial met its primary endpoint, with sonelokimab achieving statistical significance across all primary and secondary... More